A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
St. Jude Children's Research Hospital
Baylor College of Medicine
Fred Hutchinson Cancer Center
Fate Therapeutics
Center for International Blood and Marrow Transplant Research
Merck Sharp & Dohme LLC
Allogene Therapeutics
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Center for International Blood and Marrow Transplant Research
Massachusetts General Hospital
City of Hope Medical Center
Masonic Cancer Center, University of Minnesota
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
M.D. Anderson Cancer Center
Gilead Sciences
UNC Lineberger Comprehensive Cancer Center
Sana Biotechnology
St. Jude Children's Research Hospital
Celgene
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Gilead Sciences
Sana Biotechnology
Chinese PLA General Hospital
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
Dana-Farber Cancer Institute
Case Comprehensive Cancer Center
City of Hope Medical Center
Synthekine
Stanford University
Shanghai Ming Ju Biotechnology Co., Ltd.
Columbia University
University of Birmingham
Tessa Therapeutics
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Loyola University